UroGen Pharma price target raised to $47 from $23 at Scotiabank

Scotiabank raised the firm’s price target on UroGen Pharma (URGN) to $47 from $23 and keeps an Outperform rating on the shares. The firm is increasing its FDA approval likelihood from 60% to 100% and raised its price target based on its current view of a peak ZUSDURI market opportunity of about $1B, the analyst tells investors.